GLP-1 Daily: Ozempic & Wegovy News
Judge Sends Zepbound Denial Suit to Arbitration; Telehealth Sells GLP-1s for Addiction; SOUL's Kidney Fine Print
Thursday, October 22, 2026 · 6 min
A Los Angeles judge sent a patient's lawsuit, which says Anthem cut off Zepbound because it worked, to private arbitration. Also today: telehealth companies offering GLP-1s off-label for addiction, and what the SOUL trial does and doesn't show about oral semaglutide and the kidneys.
Listen
Show notes
A Los Angeles judge sent a patient's lawsuit, which says Anthem cut off Zepbound because it worked, to private arbitration. Also today: telehealth companies offering GLP-1s off-label for addiction, and what the SOUL trial does and doesn't show about oral semaglutide and the kidneys.
In this episode
- Obese Woman Ordered to Arbitrate Claims vs. Anthem Over Zepbound Denial - MyNewsLA.com — Mynewsla
““Despite this knowledge, Anthem intentionally and wrongfully refused Zepbound for Alicia simply because the drug began to work for her and lowered her weight to where she was no longer morbidly obese,” according to the suit.”
- STAT+: Telehealth leapfrogs FDA approval with off-label GLP-1 prescriptions for addiction — STAT
“But some telehealth platforms that specialize in treating addiction aren’t waiting. In the last year, a few companies have begun to market off-label prescriptions of GLP-1s, both branded and compounded, to treat alcohol use disorder and other addictions.”
- Oral Semaglutide Kidney Outcomes in SOUL | PeptideMethods — PeptideMethods
“The kidney signal in SOUL was a change in an eGFR measure, not evidence that oral semaglutide prevented kidney failure or reduced the need for dialysis.”